Biotech · Private company
Immatics US, Inc.
Track this companyFree. Adds Immatics US, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials73 recruiting or active
Pipeline programs23From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline23
- IMA203Phase 3 · Melanoma, Cutaneous MalignantClinicalTrials.gov · fetched Nov 12, 2026
- ipilimumabPhase 3 · Melanoma, Cutaneous MalignantClinicalTrials.gov · fetched Nov 12, 2026
- lifileucelPhase 3 · Melanoma, Cutaneous MalignantClinicalTrials.gov · fetched Nov 12, 2026
- nivolumabPhase 3 · Melanoma, Cutaneous MalignantClinicalTrials.gov · fetched Nov 12, 2026
- nivolumab plus relatlimabPhase 3 · Melanoma, Cutaneous MalignantClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumabPhase 3 · Melanoma, Cutaneous MalignantClinicalTrials.gov · fetched Nov 12, 2026
- IMA203 ProductPhase 2 · Refractory CancerClinicalTrials.gov · fetched Nov 12, 2026
- IMA203 product- flat dosePhase 2 · Refractory CancerClinicalTrials.gov · fetched Nov 12, 2026
- IMA203CD8 ProductPhase 2 · Refractory CancerClinicalTrials.gov · fetched Nov 12, 2026
- IMADetect®Phase 2 · Refractory CancerClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Refractory CancerClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- IMA101 productPhase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- IMA201 ProductPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- IMA202 ProductPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- IMA203Phase 1 · Cutaneous MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- IMADetectPhase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- IMADetect®Phase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- IMADetect®Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- mRNA-4203Phase 1 · Cutaneous MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Recombinant human interleukin-2Phase 1 · CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- ACTengine® IMA203 Combined With mRNA-4203PHASE1 · RECRUITING · started Jul 25, 2025ClinicalTrials.gov NCT06946225 · fetched Nov 12, 2026
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaPHASE3 · RECRUITING · started Jan 14, 2025ClinicalTrials.gov NCT06743126 · fetched Nov 12, 2026
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsPHASE1_PHASE2 · RECRUITING · started May 14, 2019ClinicalTrials.gov NCT03686124 · fetched Nov 12, 2026
- TCR-engineered T Cells in Solid Tumors: IMA202-101PHASE1 · COMPLETED · started May 2, 2019ClinicalTrials.gov NCT03441100 · fetched Nov 12, 2026
- Human Leukocyte Antigen Typing and Tumor Antigen Expression ProfilingCOMPLETED · started Feb 26, 2019ClinicalTrials.gov NCT03760952 · fetched Nov 12, 2026
- TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)PHASE1 · COMPLETED · started Dec 19, 2018ClinicalTrials.gov NCT03247309 · fetched Nov 12, 2026
- ACTolog in Patients With Solid CancersPHASE1 · COMPLETED · started Jun 30, 2017ClinicalTrials.gov NCT02876510 · fetched Nov 12, 2026